National Psoriasis Foundation's Patient Registry Begins Recruiting


People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S. psoriasis registry begins recruiting patients in 2015. The registry, a joint collaboration with the National Psoriasis Foundation and Corrona, LLC, will initially track the drug safety reporting for secukinumab, a new biologic medication by Novartis Pharmaceuticals for moderate-to-severe psoriasis. The Corrona Psoriasis Registry will enroll at least 3,000 people with psoriasis on secukinumab and follow their treatment for at least eight years. Novartis is the first subscriber to the registry and did incur a subscriber fee.
To become an investigator in the registry or learn more about it, visit
By collecting and analyzing data from thousands of people with psoriasis over many years, the registry will help clinicians, researchers and the pharmaceutical industry compare the effectiveness and safety of different psoriasis treatments. Data will be gathered through comprehensive questionnaires completed by patients and their dermatologists during appointments. In addition to studying treatment safety and effectiveness, the registry will help identify possible causes of psoriasis, examine the relationship between psoriasis and other health conditions, and study the impact of the disease on quality of life, among other outcomes.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free